Jiangsu Canopus Wisdom Medical Technology Co. Ltd. A

Dongxing Medical announced that as of July 28, 2026, the company had repurchased a total of 810,000 shares through centralized bidding, accounting for 0.80% of total share capital, with a total repurchase amount of 20 million yuan. The highest transaction price for this repurchase was 26.93 yuan per share, and the lowest was 23.46 yuan per share. In the first quarter of 2026, the company achieved revenue of 90.47 million yuan and net profit attributable to the parent of 17.92 million yuan.

Foxconn Industrial Internet announced plans to repurchase shares for no less than 1 billion yuan and no more than 2 billion yuan, with a maximum buyback price of 103 yuan per share. The company said its share price has fallen by a cumulative 20 percent over the past twenty consecutive trading days, and the buyback aims to safeguard shareholder interests and boost investor confidence. The repurchased shares will be used for sale, and any unsold portion after the deadline will be cancelled. Yushen Intelligent plans to use surplus raised funds of 15 million to 30 million yuan for a buyback, to be used for employee stock ownership plans or equity incentives, with a maximum buyback price of 46.28 yuan per share. Honggong Technology plans a buyback of 60 million to 90 million yuan, also for employee stock ownership plans or equity incentives, with a maximum buyback price of 100 yuan per share. In addition, Dongxing Medical made its first buyback of 408,000 shares for a total amount of 9.8568 million yuan; Tiannai Technology made its first buyback of 312,000 shares for a total payment of 10.0156 million yuan.

Dongxing Medical announced plans to repurchase company shares using its own funds through centralized bidding. The buyback amount will be no less than 20 million yuan and no more than 40 million yuan, with a maximum price of 41.7 yuan per share. The estimated number of shares to be repurchased ranges from 480,000 to 960,000, accounting for 0.48% to 0.96% of the total share capital. In the first quarter of 2026, the company achieved revenue of 90.47 million yuan and net profit attributable to the parent company of 17.92 million yuan.

Dongxing Medical has completed the asset transfer for its cash acquisition of a 90% equity stake in Wuhan Yijiabao Biomaterials Co., Ltd. The target company completed its industrial and commercial registration changes on July 17, obtaining a new business license issued by the Market Supervision Administration of Hongshan District, Wuhan. The delivery of the target shares has been finalized, and Dongxing Medical now directly holds a 90% stake in Yijiabao. According to the agreement, within 10 working days after the equity delivery, Dongxing Medical will pay the first installment of the equity transfer price totaling approximately 577 million yuan to the counterparty, and the payment is currently in progress.